Alpha decay and proton-neutron correlations

We study the influence of proton-neutron (p-n) correlations on alpha-decay width. It is shown from the analysis of alpha Q values that the p-n correlations increase the penetration of the alpha particle through the Coulomb barrier in the treatment following Gamow's formalism, and enlarges the total alpha-decay width significantly. In particular, the isoscalar p-n interactions play an essential role in enlarging the alpha-decay width. The so-called "alpha-condensate" in Z > 84 isotopes are related to the strong p-n correlations.Comment: 5 pages, 6 figures, accepted for publication in Phys. Rev. C (R.C.

Roles of proton-neutron interactions in alpha-like four-nucleon correlations

An extended pairing plus QQ force model, which has been shown to successfully explain the nuclear binding energy and related quantities such as the symmetry energy, is applied to study the alpha-like four-nucleon correlations in 1f_{7/2} shell nuclei. The double difference of binding energies, which displays a characteristic behavior at $N \approx Z$, is interpreted in terms of the alpha-like correlations. Important roles of proton-neutron interactions forming the alpha-like correlated structure are discussed.Comment: 10 pages, 2 figures, RevTex, submitted to Phys. Rev.

The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants

The last ten years have seen rapid strides in the evolution of nonvitamin K oral anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). For the preparation of this consensus, a comprehensive literature search was performed and data on available trials, subpopulation analyses, and case reports were analyzed. This Indian consensus document intends to provide guidance on selecting the right NOAC for the right patients by formulating expert opinions based on the available trials and Asian/Indian subpopulation analyses of these trials. A section has been dedicated to the current evidence of NOACs in the Asian population. Practical suggestions have been formulated in the following clinical situations: (i) Dose recommendations of the NOACs in different clinical scenarios; (ii) NOACs in patients with rheumatic heart disease (RHD); (iii) Monitoring anticoagulant effect of the NOACs; (iv) Overdose of NOACs; (v) Antidotes to NOACs; (vi) Treatment of hypertrophic cardiomyopathy (HCM) with AF using NOACs; (vii) NOACs dose in elderly, (viii) Switching between NOACs and vitamin K antagonists (VKA); (ix) Cardioversion or ablation in NOAC-treated patients; (x) Planned/emergency surgical interventions in patients currently on NOACs; (xi) Management of bleeding complications of NOACs; (xii) Management of acute coronary syndrome (ACS) in AF with NOACs; (xiii) Management of acute ischemic stroke while on NOACs